Even if less common, HER2 overexpression and mutation is the pathogenic driver even in other types of solid tumors, as non-small cell lung cancer (NSCLC) [6], colorectal [7], and biliary tract cancers [8]. This evidence concerns the gene ERBB2 and biliary tract neoplasm.